FDA Inspection 1218721 — Wickliffe Pharmaceutical Inc

Wickliffe Pharmaceutical Inc — FEI 3002992930

The FDA completed an inspection of Wickliffe Pharmaceutical Inc on September 15, 2023 in Lexington, KY. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Veterinary.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
September 15, 2023
Fiscal Year
2023
Product Type
Veterinary
Project Area
Monitoring of Marketed Animal Drugs, Feed, and Devices
Location
Lexington, KY (United States)